PPARα activators may play role for the regression of ventricular hypertrophy in hypertensive and hyperlipidemic patients [9]
Abstract
[No abstract available]
Description
Keywords
Antilipemic Agents , Clinical Trials , Evidence-Based Medicine , Humans , Hyperlipidemias , Hypertension , Hypertrophy, Left Ventricular , Models, Cardiovascular , PPAR alpha , Procetofen , Treatment Outcome , fenofibrate , peroxisome proliferator activated receptor alpha , antilipemic agent , fenofibrate , peroxisome proliferator activated receptor alpha , blood pressure regulation , heart muscle cell , heart ventricle hypertrophy , human , hyperlipidemia , hypertension , letter , lipid metabolism , lipoprotein metabolism , nonhuman , oxidative stress , priority journal , remission , biological model , clinical trial , drug potentiation , evidence based medicine , heart left ventricle hypertrophy , hyperlipidemia , hypertension , metabolism , treatment outcome